Pharmacological medicines (topiramate and lisdexamfetamine) that are currently approved for these eating disorders are associated with adverse side effects, such as headache, paresthesia, sedation, and increased heart rate and blood pressure
It's often called a "SPF booster": this is because it keeps UV filters properly dissolved and evenly distributed to support a sunscreen's performance
Survodutide, developed as a GLP-1/glucagon co-agonist, achieved a 14.9% weight loss over 46 weeks in a recent phase 2 trial in individuals with obesity while maintaining acceptable glycemic profiles [20]
Some vials dissolve quickly
GLP-1 receptor agonists address the hormonal drivers of hunger, glycemic control, and energy regulation that willpower alone cannot touch
The growing link between these drugs and serious eye conditions requires immediate attention from both medical and legal professionals